Pulmonary Drug Delivery Systems Market Size

  • Report ID: 4410
  • Published Date: Oct 11, 2024
  • Report Format: PDF, PPT

Pulmonary Drug Delivery Systems Market Size

Pulmonary Drug Delivery Systems Market size was over USD 60.56 billion in 2024 and is set to reach USD 140.32 billion by the end of 2037, growing at around 6.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of pulmonary drug delivery systems is assessed at USD 63.81 billion.The growth of the market can be attributed to the surge in cases of asthma worldwide, coupled with increasing instances of pulmonary disorders, and growing funding from government and private organizations for better therapy management across the globe. People are now becoming more aware of these diseases and disorders, which is further expected to fuel the market over the forecast period. According to the World Health Organization, an estimated 262 million people suffered from asthma around the world in 2019 and it caused 455 000 deaths.

Global pulmonary drug delivery systems market trends such as, technological advancements in the pharmaceutical industry, increasing consumption of tobacco and smoking, backed by exposure to air pollution, along with development in drug delivery systems owing to growing health care spending are anticipated to fuel market growth during the forecast period. For instance, in February 2022, AptarGroup, Inc. launched HeroTracker Sense, a smart connected respiratory health device, that transforms a standard metered dose inhaler (pMDI) into a digital respiratory health tool. Hence, all these factors are anticipated to boost the market’s growth over the forecast period.


Pulmonary Drug Delivery Systems Market
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 4410
  • Published Date: Oct 11, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of pulmonary drug delivery systems is assessed at USD 63.81 billion.

The pulmonary drug delivery systems market size was over USD 60.56 billion in 2024 and is set to reach USD 140.32 billion by the end of 2037, growing at around 6.8% CAGR during the forecast period i.e., between 2025-2037. Rising prevalence of chronic respiratory diseases as air pollution is increasing will boost the market growth.

North America industry is anticipated to dominate majority revenue share by 2037, due to increasing prevalence of lung diseases such as COPD, chronic bronchitis, and asthma in the region.

The major players in the market include Novartis AG, Lupin Limited, Briggs Healthcare, Inc., Boehringer Ingelheim International GmbH, Koninklijke Philips N.V., Merck & Co., Inc., 3M Company, AstraZeneca PLC, GSK plc, GF Health Products, Inc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample